L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: Therapeutic options

Presse Medicale

Volumn 42, Issue 4 PART2, 2013, Pages 523-527

  Cacoub, Patrice ^a,b   Terrier, Benjamin ^c   Saadoun, David ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AZATHIOPRINE; BOCEPREVIR; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; GLUCOCORTICOID; INTERLEUKIN 2; METHOTREXATE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; TELAPREVIR;

ANEMIA; ASTHENIA; BACTERIAL INFECTION; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULITIS;

EID: 84875612321     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.011     Document Type: Letter

References (33)

1. Cacoub P., Poynard T., Ghillani P., Charlotte F., Olivi M., Piette J.C., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999, 42:2204-2212.
2. Trejo O., Ramos-Casals M., Garcia-Carrasco M., Yague J., Jimenez S., de la Red G., et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001, 80:252-262.
3. Sansonno D., Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005, 5(4):227-236.
4. Boonyapisit K., Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002, 25:909-913.
5. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P.L., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994, 330:751-756.
6. Dammacco F., Sansonno D., Han J.H., Shyamala V., Cornacchiulo V., Iacobelli A.R., et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994, 84:3336-3343.
7. Cacoub P., Lidove O., Maisonobe T., Duhaut P., Thibault V., Ghillani P., et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002, 46:3317-3326.
8. Zuckerman E., Keren D., Slobodin G., Rosner I., Rozenbaum M., Toubi E., et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000, 27(9):2172-2178.
9. Naarendorp M., Kallemuchikkal U., Nuovo G.J., Gorevic P.D. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001, 28(11):2466-2473.
10. Mazzaro C., Zorat F., Caizzi M., Donada C., Di Gennaro G., Maso L.D., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005, 42(5):632-638.
11. Saadoun D., Resche-Rigon M., Thibault V., Piette J.C., Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006, 54:3696-3706.
12. Saadoun D., Pol S., Blanc F., Pialoux G., Karras A., Bazin D., et al. PegIFNa/Ribavirin/Protease inhibitor combination is highly effective in HCV-mixed cryoglobulinemia vasculitis. Arthritis Rheum 2012, 1657:S708. [abstract].
13. Tarantino A., Campise M., Banfi G., Confalonieri R., Bucci A., Montoli A., et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995, 47:618-623.
14. Casato M., Agnello V., Pucillo L.P., Knight G.B., Leoni M., Del Vecchio S., et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997, 90:3865-3873.
15. Hausfater P., Cacoub P., Assogba U., Lebon P., Piette J.C. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 2002, 91(4):627-630.
16. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834.
17. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003, 101:3818-3826.
18. Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19:3054-3061.
19. Cacoub P., Delluc A., Saadoun D., Landau D.A., Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?. Ann Rheum Dis 2008, 67(3):283-287.
20. Ferri C., Cacoub P., Mazzaro C., Roccatello D., Scaini P., Sebastiani M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11(1):48-55.
21. Saadoun D., Resche-Rigon M., Sene D., Perard L., Karras A., Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008, 67:1431-1436.
22. De Vita S., Quartuccio L., Isola M., Mazzaro C., Scaini P., Lenzi M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:843-853.
23. Sneller M.C., Hu Z., Langford C.A. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:835-842.
24. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F., Zaramella M., Monti M., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011, 10(11):714-719.
25. Petrarca A., Rigacci L., Caini P., Colagrande S., Romagnoli P., Vizzutti F., et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010, 116(3):335-342.
26. Terrier B., Saadoun D., Sene D., Sellam J., Perard L., Coppere B., et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term follow-up study of thirty-two patients. Arthritis Rheum 2009, 60:2531-2540.
27. Sene D., Ghillani-Dalbin P., Amoura Z., Musset L., Cacoub P. Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855.
28. Dammacco F., Tucci F.A., Lauletta G., Gatti P., De Re V., Conteduca V., et al. Pegylated interferon-{alpha}, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010, 116:343-353.
29. Saadoun D., Resche Rigon M., Sene D., Terrier B., Karras A., Perard L., et al. Rituximab plus Peg-interferon-{alpha}/ribavirin compared with Peg-interferon-{alpha}/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010, 116:326-334.
30. Landau D.A., Rosenzwajg M., Saadoun D., Trébeden-Negre H., Klatzmann D., Cacoub P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008, 58(9):2897-2907.
31. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011, 365:2067-2077.
32. Terrier B., Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol 2013, 25(1):10-18.
33. Saadoun D., de Chambrun M.P., Hermine O., Karras A., Choquet S., Jego P., et al. Rituximab plus fludarabine and cyclophosphamide is an effective treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res 2012, [Epub ahead of print]. 10.1002/acr.21856.